Home > Cardiology > ACC 2021 > Interventional and Structural Cardiology > Clopidogrel monotherapy associated with better net outcomes relative to aspirin monotherapy 6-18 months after PCI

Clopidogrel monotherapy associated with better net outcomes relative to aspirin monotherapy 6-18 months after PCI

Presented By
Prof. Hyo-Soo Kim, Seoul National University Hospital, South Korea
Conference
ACC 2021
Trial
HOST-EXAM
The open-label HOST-EXAM study showed that clopidogrel monotherapy was associated with better net outcomes relative to aspirin in patients who were event-free for 6–18 months following percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) over a 2-year follow-up period [1,2]. In patients who have undergone PCI, guidelines suggest 6–12 months of dual antiplatelet therapy (DAPT), typically with aspirin plus a P2Y12 inhibitor such as clopidogrel. After the initial 6–12 month period, lifetime aspirin monotherapy is recommended. Prof. Hyo-Soo Kim (Seoul National University Hospital, South Korea) and colleagues aimed to explore whether an alternative monotherapy could achieve superior clinical outcomes compared with aspirin. The primary endpoint was a composite of all-cause death, acute coronary syndrome including non-fatal MI, stroke, the need for revascularisation while under antiplatelet ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on